MedTrace Logo

NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients

NCT02274025 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2018-03-29

No results posted yet for this study

Summary

NovellusDx technology identifies tumor-specific driver mutations, but unlike sequencing-based tests, NovellusDx has a functional assay that detects dis-regulated translocation of mutated signaling proteins to the nucleus. This allows NovellusDx to identify functionally-impactful driver mutations regardless of whether the mutation has previously been described or linked to a tumor type.

Conditions

Sponsors & Collaborators

  • Rabin Medical Center

    collaborator OTHER

  • Fore Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Mordechai Kremer, Prof · Rabin Medical Center, Beilinson

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02274025 on ClinicalTrials.gov